Kandice buys ICPT 244.98: Intercept Pharmaceuticals Now Covered by Analysts at Goldman Sachs (ICPT)
Goldman Sachs began coverage on shares of Intercept Pharmaceuticals (NASDAQ:ICPT) in a report released on Wednesday, TheFlyOnTheWall.com reports. The firm issued a neutral rating and a $265.00 price objective on the stock. ICPT has been the subject of a .. ...
45 people liked this
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home